Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 7/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 3/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19841039 | 0.88 | PRKCI (0.38) | KDM4EHTTHASPINKDM5AKDM5B | |
| SCHEMBL15782860 | 0.78 | CA12 (0.44) | KDM4EHTTPRKCICA12POLB | |
| SCHEMBL15782872 | 0.73 | PRKCI (0.33) | PRKCI | |
| SCHEMBL15782875 | 0.69 | CYP3A4 (0.44) | KDM4EHTT | |
| SCHEMBL25065370 | 0.68 | DAO (0.44) | KDM4EHASPIN | |
| SCHEMBL19170648 | 0.68 | MAOA (0.40) | KDM4EHTTHASPINHIPK2MAOA | |
| SCHEMBL19725753 | 0.68 | HASPIN (0.44) | HASPIN | |
| SCHEMBL9867109 | 0.68 | DHODH (0.45) | KDM4EKDM5AKDM5BHIPK2 | |
| SCHEMBL17193018 | 0.67 | ADORA3 (0.44) | KDM4EHTTHIPK2MAOAMAPK10 | |
| SCHEMBL15782870 | 0.67 | PRKCI (0.37) | KDM4EPRKCICA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190345116-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3138831-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | President and Fellows of Harvard College (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163238-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | KDM4E 800/4885HTT 94/4885HASPIN 513/4885 |
| US-20190345116-A1 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF | TET1, TET3, MYC | KDM4E 800/4885HTT 94/4885HASPIN 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.